Keen Eye and Ultivue Announce Collaborative Agreement to Propel Multiplex and Spatial Analysis in Clinical Research
Keen Eye, a leading AI company in digital pathology for clinical research and Ultivue, Inc. an industry leader in multiplexing tools and novel image analysis solutions for tissue biomarker studies, announce a collaborative agreement to promote multiplexed immunofluorescence (mIF) assays and scalable AI applications to unlock spatial analysis in clinical research.
Ultivue develops unique solutions for use in mIF applications, imaging and spatial phenomics. Its proprietary InSituPlex® technology enabling improved signal to noise data is designed for fast and comprehensive exploration of biologically relevant targets, up to 12-plex, with same slide-H&E analysis in tissue samples. This technology combines the power of computational pathology & spatial biology to guide translational science in immuno-oncology.
Ultivue recognizes the need for dedicated and custom AI models to analyze the complexity of mIF data at scale and to provide improved turn-around times and consistent readouts across large cohorts “We are looking forward to accelerating data generation for biopharma customers from mIF kits by partnering with Keen Eye. We can jointly support more scalable workflows which will allow us to meet increasing demand in clinical trials.” said Florian Leiss, Ph.D. Vice President Digital Health Strategies at Ultivue.
Keen Eye is an AI Platform company dedicated to deliver accurate, standardized, and undiscovered tissue insights in research and clinical development using Deep Learning histopathology digital image analysis. Its proprietary models dedicated for spatial exploration of tumor microenvironment give access to reliable tissue segmentation, biomarker quantification, cell population profiling, and morphological discovery.
Thanks to Ultivue’s pre-optimized assays, the high accuracy achieved for every biomarker will drastically reduce errors during quantification steps as phenotypes combine several biomarkers. As Dr. Sylvain Berlemont, Keen Eye’s founder and CEO says, “We are thrilled to expand our application portfolio combined with best-in-class Ultivue mIF assays to biopharma companies and CROs. This partnership will undeniably support our customers to fully extend reproducibility and scalability throughout their clinical research.”.
About Keen Eye
Keen Eye is a health technology company based in Paris, aiming to bring AI into every research laboratory, CRO and pharmaceutical company, for the benefit of biologists, pathologists, and patients. Keen Eye is building decision-support and GCLP-compliant image analysis solutions relying on Deep Learning technology through web-based platforms. Keen Eye strives to support the development of new therapies with better, faster, and accurate analytics. Learn more at keeneye.ai.
About Ultivue
Ultivue provides researchers and scientists in translational medicine with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex® technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions coupled with our scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs. Learn more at Ultivue.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005704/en/
Contact information
Keen Eye
Sylvain Berlemont, Ph.D
CEO and Founder
sylvain.berlemont@keeneye.ai
Ultivue
Florian Leiss Ph.D
Vice President Digital Health Strategies
Florian.leiss@ultivue.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
P.I. Works Drives Stronger Network Results for Beeline Uzbekistan2.12.2025 11:00:00 EET | Press release
P.I. Works celebrates the success of its long-time client Beeline Uzbekistan, recognized by independent global analytics firms Opensignal and Ookla for excellence in mobile network performance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202914682/en/ P.I. Works Drives Stronger Network Results for Beeline Uzbekistan Opensignal named Beeline Uzbekistan the country’s Fastest Mobile Internet provider and Most Consistent Mobile Network for the first half of 2025, while Ookla recognized the operator with the Best Mobile Video Experience award. These honors reflect the measurable impact of P.I. Works’ AI-driven automation, analytics, and optimization capabilities, combined with Beeline Uzbekistan’s strong commitments to investment and innovation. Partnership Powering Network Excellence A joint strategy to bring intelligence and efficiency into operations fuels this success. With automation, self-organizing capabilities, and
GMA with MOVIVA ® : setting new standards in endoscopic bariatric treatment2.12.2025 10:59:00 EET | Press release
Just a few months after the world’s first Gastric Mucosal Ablation (GMA) case using MOVIVA® at the Policlinico Universitario Agostino Gemelli in Rome, clinical experience is rapidly expanding across Europe. With around 80 procedures performed within a short timeframe in eight countries, MOVIVA® is helping to establish a new era of endoscopic bariatric treatment – offering a less invasive option as obesity rates continue to rise worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202355726/en/ GMA with MOVIVA® A promising alternative for bariatric patients: GMA with MOVIVA® GMA is an incisionless, minimally invasive endoscopic procedure. It targets the gastric fundus, the main site of ghrelin production – the so-called hunger hormone. By reducing ghrelin levels, patients experience less hunger. At the same time, the ablated tissue shrinks the fundus, which reduces stomach capacity. Together, these effects can support
Hanshow Achieves SOC 2 Type II and SOC 3 Certifications, Elevating Data Security Standards for Global Retailers2.12.2025 10:53:00 EET | Press release
Hanshow, a global leader in digital retail solutions, announced that its All-Star digital solution has earned SOC 2 Type II and SOC 3 certifications following an independent audit by Deloitte. These internationally recognized certifications underscore Hanshow’s commitment to robust data security, privacy protection, and operational reliability for retailers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201803690/en/ All-Star of Hanshow has earned SOC 2 Type II certification. The SOC 2 and SOC 3 certifications, established by the American Institute of Certified Public Accountants (AICPA), are trusted global standards for evaluating information security, processing integrity, confidentiality, and privacy across technology service organizations. SOC 2 Type II certification assesses the operational effectiveness of security controls over an extended period, while SOC 3, as its public summary, offers customers clea
Klarna Launches Tap to Pay for In-Store Purchases Across 14 Markets2.12.2025 10:00:00 EET | Press release
Klarna, the global digital bank and flexible payments provider, today launches the brand new feature Tap to Pay across 14 European markets, bringing flexible payments into physical retail at scale and transforming the Klarna app into an everyday contactless wallet. With more than 80% of European shopping still happening in physical stores, Tap to Pay brings consumers the ease of online shopping into the bricks and mortar stores. Instead of hunting for cards or juggling apps, everything sits in one place — the Klarna app — making every purchase smoother from start to finish. Utilising NFC technology, Tap to Pay turns the Klarna app into a contactless wallet, letting consumers set up a flexible payment plan and pay with a tap, all in one place – without adding their card to another wallet or switching apps at checkout. Tap to Pay builds on the rapid global uptake of the new debit-first Klarna Card, now used by more than 4 million consumers. The card is debit by default, with the option t
SkillOnNet Redefines RNG Gaming with World-First Launch of AI-Powered GAIA Roulette2.12.2025 10:00:00 EET | Press release
Global entertainment brand SkillOnNet has announced the launch of GAIA Roulette, a groundbreaking new roulette experience powered by artificial intelligence. The game – which is now live on PlayUZU Mexico, with plans to expand to additional markets across the SkillOnNet network in the coming months – blends the thrill of RNG gameplay with the 3D realism of a live dealer. It’s the world’s first AI-driven roulette host now in commercial use. Unlike traditional RNG tables, GAIA Roulette features an intelligent, interactive digital dealer that is personalized to each player. GAIA learns player preferences, adapts its communication style, and provides real-time assistance, helping users understand bets, game flow, and strategies. Players can discuss game events – asking questions about game results, previous numbers, their wins and losses, and review gameplay history – but they can also talk about everyday topics like hobbies, sports, foods, movies, weather and more to make the experience m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom